Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Kronos Bio's Istisociclib?
Istisociclib is a small molecule commercialized by Kronos Bio, with a leading Phase II program in Germ Cell Tumors;Uterine Cancer;Epithelial...
Data Insights
Risk adjusted net present value: What is the current valuation of Kronos Bio's Istisociclib?
Istisociclib is a small molecule commercialized by Kronos Bio, with a leading Phase II program in Small-Cell Lung Cancer. According...